Trump’s Plan To Lower Drug Prices Through Targeting Rebates Would Cost Taxpayers $177 Billion

The Congressional Budget Office report concluded that the proposal to curtail rebates in the drug system would be unlikely to force drug companies to lower list prices across the board. Instead, they would reimburse pharmacies for discounts provided to individual seniors as they fill their prescriptions. In other pharmaceutical news: an aspiring drugmaker's battle with federal regulators, Cigna's strong performance in the pharmacy-benefits business, and more.

from Kaiser Health News http://bit.ly/2LmlDeL